SC 13G/A: Cellectar Biosciences, Inc.

AI Summary

SC 13G/A filing by Cellectar Biosciences, Inc..

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• rosalind_clrb_13ga6_july.htm (SC 13G/A) — 103KB
• rosalind_clrb_exa.htm (EX-99.A BD-DIR-RESOL) — 3KB
• 0001622627-24-000039.txt ( ) — 108KB

Ownership

Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: Rosalind Master Fund L.P. is the record owner of 2,098,185 shares of common stock. Rosalind Opportunities Fund I L.P is the record owner of 607,431 shares of common stock. Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares. (b) Percent of class: Rosalind Advisors, Inc. – 9.9% Rosalind Master Fund L.P. – 9.9% Rosalind Opportunities Fund I L.P. - 5.9% Steven Salamon – 9.9% Gilad Aharon – 9.9% NYC#: 139632.2 CUSIP No. 15117F500 13G/A Page 9 of 10 Pages (c) Number of shares as to which the person has: (i) Shared power to vote or to direct the vote Rosalind Advisors, Inc. – 2,709,516 Rosalind Master Fund L.P. – 2,098,185 Rosalind Opportunities Fund I LP– 607,431 Steven Salamon – 2,705,616 Gilad Aharon - 2,705,616 (ii) Sole power to dispose or to direct the disposition of Gilad Aharon – 3,900 (iii) Shared power to dispose or to direct the disposition of Rosalind Advisors, Inc. – 2,709,516 Rosalind Master Fund L.P. – 2,098,185 Rosalind Opportunities Fund I LP– 607,431 Steven Salamon – 2,705,616 Gilad Aharon - 2,705,616 Instruction . For computations regarding securities which represent a right to acquire an underlying security see 240.13d-3(d)(1).

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following . Instruction . Dissolution of a group requires a response to this item.

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

– 9. Not Applicable

Item 7 – 9. Not Applicable NYC#: 139632.2 CUSIP No. 15117F500 13G/A Page of 10 Pages

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 7/9/2024 Date Signature Steven Salamon/President Rosalind Advisors, Inc. Name/Title Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Cellectar Biosciences, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: _____________________________ Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: _____________________________ Name: Mike McDonald Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund) By: _____________________________ Name: Steven Salamon Rosalind Opportunities Fund I L.P. By: _____________________________ Name: Steven Salamon Title: Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I) NYC#: 139632.2

View Full Filing

View this SC 13G/A filing on SEC EDGAR